Brind.
  1. MediWound announced multiple clinical partnerships on August 14, 2025, including collaborations with Kerecis, MiMedx, Convatec, and Essity.

MiMedx invested in Vaporox, a Denver-based company, and Vaporox's Vaporous Hyperoxia Therapy received 510(k) clearance from the FDA for its wound care offerings.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MiMedx invested in Vaporox, a Denver-based company, and Vaporox's Vaporous Hyperoxia Therapy received 510(k) clearance from the FDA for its wound care offerings.

Who's involved

What this event is mainly about
MiMedx

Keep exploring

Part of

MediWound announced multiple clinical partnerships on August 14, 2025, including collaborations with Kerecis, MiMedx, Convatec, and Essity. All 1 developments

The entities involved

  • MiMedx

    biomedical company based in Marietta, Georgia, founded in 2008

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswireMIMEDX Announces Strategic Collaboration with Vaporox, Inc. Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia T